OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod
MWN-AI** Summary
OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical firm, has officially announced that its lead asset, OK-101, has been assigned the United States Adopted Name (USAN) "urcosimod." This milestone highlights the company's dedication to addressing significant unmet medical needs in ophthalmology, particularly for neuropathic corneal pain (NCP) and inflammatory dry eye disease (DED). The suffix "-mod" in urcosimod signifies its role as a modulator of key inflammatory and neuropathic pathways, critical for treating these ocular conditions.
Urcosimod is currently undergoing a Phase 2 clinical trial for NCP, a debilitating condition magnified by a lack of FDA-approved treatments. CEO Gary S. Jacob expressed optimism about the progress of urcosimod, especially after positive outcomes from prior trials demonstrating its efficacy in relieving pain and a favorable safety profile for DED. The unique formulation of urcosimod utilizes a lipid-conjugated platform that enhances targeting of ocular G-protein coupled receptors, presenting both anti-inflammatory and analgesic properties that distinguish it from conventional treatment modalities.
The ongoing clinical trial for NCP began in October 2024, and OKYO Pharma anticipates sharing top-line results by the fourth quarter of 2025. NCP, often marked by chronic pain and sensitivity, has no FDA-approved therapies, underscoring the significance of urcosimod’s development. By securing its USAN designation, OKYO Pharma is reinforcing its commitment to creating innovative therapeutic solutions that could substantially improve the quality of life for patients grappling with these challenging eye conditions. Further information about OKYO Pharma and urcosimod can be found on their official website.
MWN-AI** Analysis
OKYO Pharma Limited (NASDAQ: OKYO) has achieved a significant milestone with the official assignment of a United States Adopted Name (USAN) "urcosimod" for its lead asset, formerly known as OK-101. This designation not only symbolizes an advancement in the development of innovative therapies for neuropathic corneal pain (NCP) and inflammatory dry eye disease (DED) but also enhances the company's credibility in the competitive biopharmaceutical landscape.
Urcosimod’s dual action as an anti-inflammatory and analgesic offers a compelling profile, particularly given the current lack of FDA-approved treatments for NCP, a condition that affects patient quality of life severely. With ongoing clinical trials and promising results from previous studies, there is a considerable market potential, especially as DED represents a multi-billion-dollar market.
Investors should consider the implications of the Phase 2 clinical results for urcosimod, expected in Q4 2025. Successful outcomes could enhance market perceptions and drive stock value significantly, given the strong unmet need in this therapeutic area. The recent USAN assignment suggests that the company is progressing towards commercialization, which could attract interest from larger pharmaceutical entities or boost investor confidence.
However, the biopharmaceutical sector is inherently risky. Investors should closely monitor developments surrounding the Phase 2 trials and subsequent regulatory steps. A robust pipeline and successful trial outcomes will be critical for OKYO's future performance. Additionally, investors should keep an eye on market reactions to the trial results and broader market trends in the biopharmaceutical space.
In summary, while OKYO Pharma presents a potentially rewarding opportunity, it is crucial for investors to stay informed about upcoming trial results and the dynamic nature of the pharmaceutical market. Investing based on careful analysis of these developments could lead to favorable outcomes.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
LONDON and NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory dry eye disease (DED), a multi-billion-dollar market, is pleased to announce that its lead asset, OK-101, has been officially assigned the United States Adopted Name (USAN) "urcosimod".
The USAN designation reflects Okyo Pharma’s commitment to developing new therapies for unmet medical needs in ophthalmology. The suffix “-mod” in urcosimod denotes its classification as a modulator of key inflammatory and neuropathic pathways, critical to addressing ocular conditions such as neuropathic corneal pain (NCP) and dry eye disease (DED).
The USAN program, jointly managed by the American Medical Association (AMA), the United States Pharmacopeial Convention (USP), and the American Pharmacists Association (APhA), assigns unique nonproprietary names to pharmaceutical substances to ensure clarity in medical communication. This naming milestone underscores the progress of urcosimod (OK-101) in its clinical development program.
Gary S. Jacob, Ph.D., Chief Executive Officer of Okyo Pharma, commented:
“We are thrilled to announce that OK-101 has been granted the name urcosimod, marking an important step in its development as a therapeutic option for patients suffering from serious ocular conditions. Urcosimod is currently in a Phase 2 clinical trial for neuropathic corneal pain, an area of significant unmet medical need. This follows the encouraging results observed in our prior Phase 2 trial of urcosimod for dry eye disease, where the drug demonstrated strong pain reducing effects and a favorable safety profile.”
Dr. Jacob continued: “Neuropathic corneal pain is a debilitating condition for which there are currently no FDA-approved treatments. We believe urcosimod’s dual anti-inflammatory and analgesic properties uniquely position it to address both the symptoms and the underlying causes of this condition. With the USAN name granted, we are further cementing the path forward for this promising therapeutic candidate.”
Okyo Pharma’s innovative lipid-conjugated small molecule platform enables urcosimod to target and modulate ocular G-protein coupled receptors (GPCRs), reducing inflammation and pain at the source. The drug’s design, combining anti-inflammatory and pain-modulating properties, sets it apart from traditional approaches in ocular disease treatment.
The ongoing Phase 2 trial for neuropathic corneal pain was initiated in October 2024. The company is planning to release top-line results in Q4 2025.
Okyo Pharma remains committed to addressing the unmet needs of patients with sight-threatening and quality-of-life-impacting conditions.
About NCP
Neuropathic corneal pain (NCP) is a condition that causes pain and sensitivity of the eyes, face, or head. The exact cause of NCP is unknown but thought to result from nerve damage to the cornea combined with inflammation . NCP, which can exhibit as a severe, chronic, or debilitating condition in patients suffering from a host of ophthalmic conditions, is presently treated by various topical and systemic treatments in an off-label fashion. Notably, there is no FDA approved drug to treat this debilitating condition.
About Urcosimod (Formerly called OK-101)
Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response, as well as on neurons and glial cells in the dorsal root ganglion. Urcosimod was developed using a membrane-anchored-peptide technology to produce a novel long-acting drug candidate for treating dry eye disease. Urcosimod has been shown to produce anti-inflammatory and pain-reducing activities in mouse models of dry eye disease and corneal neuropathic pain (NCP), respectively, and is designed to combat washout through the inclusion of the lipid anchor built into the drug molecule to potentially enhance the residence time of urcosimod within the ocular environment. Urcosimod showed clear statistical significance in multiple endpoints in a recently completed Phase 2, multi-center, double-masked, placebo-controlled trial to treat DED, and is presently being evaluated in a randomized, placebo-controlled, double-masked Phase 2 trial to treat 48 NCP patients.
About OKYO
OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of NCP and DED, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat NCP and inflammatory DED. In addition to the completed Phase 2 trial of urcosimod to treat DED patients, OKYO is also currently evaluating urcosimod to treat NCP patients in a Phase 2 trial.
For further information, please visit www.okyopharma.com .
Enquiries:
| OKYO Pharma Limited | Gary S. Jacob, Chief Executive Officer | 917-497-7560 |
| Business Development & Investor Relations | Paul Spencer | +44 (0)20 7495 2379 |
FAQ**
Given the recent advances in OKYO Pharma's drug urcosimod, how do you foresee the potential impact of this development on investor interest in biotech stocks listed on both NASDAQ and LSE?
With urcosimod progressing through clinical trials and considering market competition, what strategies will OKYO Pharma utilize to engage investors both in the U.S. and on the LSE?
As OKYO Pharma's development of urcosimod continues, how might its success or failure influence investor sentiment in similar therapeutic ventures listed on options like LSE?
How does the assignment of the USAN name "urcosimod" by OKYO Pharma enhance the company's position for attracting investment from institutions focusing on biotechnology listed on both NASDAQ and LSE?
**MWN-AI FAQ is based on asking OpenAI questions about OKYO Pharma Limited (NASDAQ: OKYO).
NASDAQ: OKYO
OKYO Trading
0.0% G/L:
$1.68 Last:
15,469 Volume:
$1.69 Open:
